Sangamo Therapeutics, Inc. Announces Board Changes
April 25, 2020 at 09:24 am EDT
Share
Sangamo Therapeutics reported the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. McClung will oversee commercial strategic planning, alliance management and corporate and business development. From 2015 through 2019, McClung was Vice President and General Manager of Global Oncology Commercial at Amgen, which he joined from Onyx Pharmaceuticals where he had served as Chief Commercial Officer. Stephane Boissel, Executive Vice President of Corporate Strategy, will leave Sangamo at the end of July and eventually return to an entrepreneurial project. Boissel joined Sangamo in 2018 following the acquisition of TxCell (now Sangamo France), where he had served as CEO.
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
SANGAMO THERAPEUTICS, INC. 
